J.P. Morgan Healthcare Conference: signals for a re-rating of the sector are gaining momentum

Market commentary, January 26, 2026    

J.P. Morgan Healthcare Conference: signals for a re-rating of the sector are gaining momentum

By Marcel Fritsch, Head of Healthcare Fonds & Mandate, Bellevue Asset Management

The global healthcare sector is once again moving into sharper strategic focus for investors. The J.P. Morgan Healthcare Conference 2026 in San Francisco – the most important investor conference in the healthcare space at the start of the year – conveyed a picture of increasing stabilization and clearer differentiation. Following a period of political uncertainty and volatile valuations, investor attention is shifting back toward fundamental factors. Operational execution, innovative strength and disciplined capital allocation are gaining importance. For long-term-oriented investors, this creates an environment in which the healthcare sector offers not only defensive characteristics, but also selective growth opportunities. This development provides the foundation for a strategic re-rating of the sector.

More predictability, less pricing pressure

A key signal from the conference was the clear easing of concerns around price regulation, particularly in the US. Leading pharmaceutical companies reported that recent agreements with the US government are viewed as limited in scope and manageable. This increases planning visibility for the coming years and reduces a key macro risk. Developments in Europe point in a similar direction. Political pressure is growing to ensure appropriate remuneration for medical innovation, especially for new product launches. As a result, companies are gaining negotiating leverage, and launch strategies are being managed more actively. Pricing issues are therefore losing their dominant influence on valuations, while innovation and commercial execution are moving further into focus.

Biotech: operational progress supports sentiment

In the biotech and pharma sector, the focus was less on takeover speculation and more on operational progress. Following a pronounced M&A phase in the previous year, the conference saw limited activity in terms of new deals, but the overall operational signals were constructive. Preliminary financial figures and updated guidance provided a degree of stability. From an investor perspective, visible progress in product launches and pipelines was key. BridgeBio demonstrated increasing market traction with Attruby in the treatment of ATTR cardiomyopathy and has several near-term clinical catalysts. Madrigal reinforced confidence in the sustainable demand for Rezdiffra, supported by rising diagnosis rates in liver diseases and the build-out of a long-term, scalable franchise. BioNTech stood out with the breadth and depth of its oncology pipeline and a high density of late-stage clinical programs. Overall, innovation is once again being assessed in a more differentiated manner, with operational execution increasingly shaping investor confidence.

Medtech: Penumbra acquisition sets a marker

The medtech sector confirmed its structural strength and operational stability. Discussions with large companies indicated that business trends remain largely on track and that full-year targets appear achievable. Intuitive Surgical reported a marked increase in procedure volumes, underscoring robust underlying medical demand. A clear strategic signal was set by Boston Scientific with the USD 14.5 bn acquisition of Penumbra, a provider of innovative therapies with strong growth potential. In addition, Penumbra significantly exceeded market expectations in terms of revenue growth. Positive momentum is also evident in adjacent segments. Companies that had previously shown weaker performance are returning to a growth trajectory, while life science tools providers are benefiting from a gradual recovery in demand. Overall, the segment remains a key innovation driver within the healthcare system.

Conclusion: attractive valuations require active selection

The healthcare sector currently offers investors an attractive entry point. Despite improving operational visibility and strengthening fundamentals, many companies continue to trade at valuation discounts relative to the broader equity market. At the same time, dispersion within the sector remains pronounced. While some companies are benefiting from innovation, successful product launches and structural growth, others are lagging behind. For investors, this means that broad market exposure falls short. Value creation increasingly depends on active selection and in-depth analysis of business models, pipeline quality and execution capabilities. In this environment, healthcare can once again be positioned as a strategically relevant core allocation that combines stability with growth.

Detailed information about our healthcare investment solutions can be found on our website.

Contact
Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich
Tanja Chicherio, +41 44 267 67 00, tch@bellevue.ch, www.bellevue.ch
 

Bellevue – Excellence in Specialty Investments
Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 90 professionals, generates attractive investment returns and creates value added for clients and shareholders alike. Bellevue managed CHF 4.8 bn in assets as of June 30, 2025.

Disclaimer
This marketing document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient. This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and only on the basis of the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: Zeidler Legal Process Outsourcing Limited, 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Information agent: Zeidler Legal Process Outsourcing Ltd., SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (PRIIP-KIID), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above-mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Theaterstrasse 12, CH-8001 Zurich. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.